ReviewChinese journal of cancer2016
Cell-free circulating tumor DNA in cancer.
Review in Chinese journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association Between Liquid Biopsy and Prognosis of Gastric Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Evaluating Cell-Free DNA Quantification and Integrity in Breast Cancer Using Fluorometric, Electrophoretic and PCR-Based Platforms.Methods and protocols · 2026Article
- Review
- Article
- Progress in enzyme-powered micro/nanomotors in diagnostics and therapeutics.Bioactive materials · 2025Review
- Non-invasive early-stage cancer detection: current methods and future perspectives.Clinical and experimental medicine · 2024Review
- Impact of Molecular Profiling on Therapy Management in Breast Cancer.Journal of clinical medicine · 2024Review
- The ctDNA revolution: Insights on cancer care: A narrative review.Bioinformation · 2024Article
- Extracellular Vesicles Are Important Mediators That Regulate Tumor Lymph Node Metastasis via the Immune System.International journal of molecular sciences · 2023Review
- Identification of Small GTPases That Phosphorylate IRF3 through TBK1 Activation Using an Active Mutant Library Screen.Biomolecules & therapeutics · 2023Article
- Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility.International journal of molecular sciences · 2022Review
- Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Review
- Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer.Cancer informatics · 2022Review
- Near-Infrared Light Regulation of Capture and Release of ctDNA Platforms Based on the DNA Assembly System.Frontiers in bioengineering and biotechnology · 2022Article
- Circulating Bacterial DNA: A New Paradigm for Cancer Diagnostics.Frontiers in medicine · 2022Review
- WisecondorFF: Improved Fetal Aneuploidy Detection from Shallow WGS through Fragment Length Analysis.Diagnostics (Basel, Switzerland) · 2021Article
- Article
- Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease.Cancers · 2021Review
- Role of cell-free network communication in alcohol-associated disorders and liver metastasis.World journal of gastroenterology · 2021Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer is a common cause of death worldwide. Despite significant advances in cancer treatments, the morbidity and mortality are still enormous. Tumor heterogeneity, especially intratumoral heterogeneity, is a significant reason underlying difficulties in tumor treatment and failure of a number of current therapeutic modalities, even of molecularly targeted therapies. The development of a virtually noninvasive "liquid biopsy" from the blood has been attempted to characterize tumor heterogeneity. This review focuses on cell-free circulating tumor DNA (ctDNA) in the bloodstream as a versatile biomarker. ctDNA analysis is an evolving field with many new methods being developed and optimized to be able to successfully extract and analyze ctDNA, which has vast clinical applications. ctDNA has the potential to accurately genotype the tumor and identify personalized genetic and epigenetic alterations of the entire tumor. In addition, ctDNA has the potential to accurately monitor tumor burden and treatment response, while also being able to monitor minimal residual disease, reducing the need for harmful adjuvant chemotherapy and allowing more rapid detection of relapse. There are still many challenges that need to be overcome prior to this biomarker getting wide adoption in the clinical world, including optimization, standardization, and large multicenter trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.